Invivyd Inc
0.015 (1.27%)


Draw Mode:

Volume 487,597
Bid Price 1.16
Ask Price 1.28
News (2)
Day High 1.24


52 Week Range


Day Low 1.14
Company Name Stock Ticker Symbol Market Type
Invivyd Inc IVVD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.015 1.27% 1.20 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.19 1.14 1.24 1.20 1.185
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,988 487,597 $ 1.20 $ 584,098 - 1.03 - 4.89
Last Trade Time Type Quantity Stock Price Currency
19:22:50 1 $ 1.24 USD

Invivyd Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 131.03M 109.19M 17.74M $ - $ - -2.23 -21.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 3.13M 1.90%

more financials information »

Invivyd News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No IVVD Message Board. Create One! See More Posts on IVVD Message Board See More Message Board Posts

Historical IVVD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.381.481.031.32216,532-0.18-13.04%
1 Month1.771.9451.031.54218,959-0.57-32.2%
3 Months1.572.681.031.85228,222-0.37-23.57%
6 Months3.,530-1.80-60.0%
1 Year4.704.891.032.53287,414-3.50-74.47%
3 Years4.704.891.032.53287,414-3.50-74.47%
5 Years4.704.891.032.53287,414-3.50-74.47%

Invivyd Description

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.